Remove 2015 Remove Biopharma Remove Healthcare Provider Remove Patients
article thumbnail

Navigating the rapidly changing oncology treatment landscape: how digital tools can help

Impetus Digital

In fact, for the past five years, the number of treated patients with cancer has seen an average annual increase of 5% globally (1). This competitive intensity tends to focus on smaller patient populations with multiple treatment options (1,2). However, with rapid growth comes growing pains.

article thumbnail

Harnessing the Power of Generational Diversity as a Competitive Advantage

PM360

Today’s workforce includes Traditionalists (born 1927-1945), Boomers (1946-1964), Gen X (1965-1980), Millennials (1981-1996), and Gen Z (1997-2015). Patients are more motivated to pay attention, act, and follow a treatment plan when they recognize themselves in the marketing.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

U.S. market access landscape: A push for control is erasing the boundary between payers and providers in U.S. healthcare

Clarivate

Health systems will buy or establish an insurance plan to serve as an extension of their continuum of care, a means of directing referral streams to increase revenue and securing control over clinical and formulary decisions for patients.

article thumbnail

Global Biopharma Launches in the New World Order

PM360

Biopharma blockbusters in the last 10 years show a disturbing trend. As a top 10 biopharma company leader shared with us, “Real blockbusters are gone. Then between 2005-2015, there were 110 global blockbuster launches, with a high concentration in specialty care and biologics. In oncology, it’s 47% less.

article thumbnail

Building CO2-neutral, defossilised supply chains for chemicals

European Pharmaceutical Review

Furthermore, entire value chains must be redesigned and the CO 2 emitters (especially point source emitters), chemical industry and power sector, downstream users, eg, healthcare industries and their customers, and healthcare providers need to be coordinated, informed, sensitised and must work out contractual frameworks to de-risk the investments.